Galectin Therapeutics GALT
NASDAQ GALT
$3.88 -0.03 (-0.77%)
At close: Sep 30, 2026 · 4:00 PM EDT

Galectin Therapeutics (GALT) Current Deferred Revenue (2010 - 2012)

Updated

Galectin Therapeutics' Current Deferred Revenue came in at $200,000 for Q2 2012, unchanged from $200,000 a year earlier and unchanged from the prior quarter.

Analysis

Galectin Therapeutics (GALT) Current Deferred Revenue (2010 - 2012) Analysis & Trends

Going back to Q4 2010, Galectin Therapeutics' Current Deferred Revenue data covers 6 quarters.

  • Going back by year, Current Deferred Revenue was $200,000 in FY2010.
  • Business Quant data shows GALT's Current Deferred Revenue at $200,000 (Q1 2012), $200,000 (Q4 2011) and $200,000 (Q3 2011) in the three quarters before Q2 2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Galectin Therapeutics 257.29 Mn 257.29 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2012 200,000.00
Mar 31, 2012 200,000.00
Dec 31, 2011 200,000.00
Sep 30, 2011 200,000.00
Jun 30, 2011 200,000.00
Dec 31, 2010 200,000.00
API Access

Galectin Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=GALT&period=max&api_key=YOUR_API_KEY